Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 6Blastic Plasmacytoid Dendritic Cell Neoplasm 3Myelodysplastic Syndromes 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

Specimen Handling 7Biopsy 6Cyclophosphamide 5ruxolitinib 4Mycophenolic Acid 4Busulfan 4fludarabine phosphate 3fludarabine 3Whole-Body Irradiation 3Tacrolimus 3Melphalan 3Injections 3Decitabine 3Cyclosporine 3Azacitidine 3venetoclax 2decitabine and cedazuridine drug combination 2Sirolimus 2Methotrexate 2Granulocyte Colony-Stimulating Factor 2veliparib 1tocilizumab 1tagraxofusp 1posaconazole 1peginterferon alfa-2b 1onvansertib 1merphos 1iadademstat 1gilteritinib 1fedratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × tagraxofusp × 1 year × Clear all
NCT05038592 2026-04-14

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
64 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡